Dermatology Department, University of Patras, Greece, University General Hospital of Patras, Rio, Greece.
J Dermatolog Treat. 2022 Mar;33(2):682-684. doi: 10.1080/09546634.2020.1789049. Epub 2020 Jul 7.
Dupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor alpha subunit of the IL-4 and IL-13 receptor. This novel agent has received a license for the treatment of moderate-to-severe atopic dermatitis in patients aged ≥12 years. However, data on the dupilumab use in the pediatric population are still extremely limited. This report aims to summarize the existing data on the on- and off-label use of dupilumab for dermatologic conditions in children and adolescents.
The current study is an overview of all the reported evidence on dupilumab for dermatologic conditions in the pediatric population. MEDLINE (PubMed), clinicaltrial.gov databases and SCOPUS were thoroughly scanned for related articles.
A small number of clinical trials, case series and case reports, that indicate a satisfactory therapeutic outcome for dupilumab in pediatric patients for certain dermatologic conditions, is present in the literature.
More long-term studies in larger patient groups are necessary so as to be able to draw definite conclusions concerning the efficacy and safety of dupilumab in pediatric patients with skin diseases.
度普利尤单抗是一种单克隆抗体，靶向白细胞介素（IL）-4 受体α亚基的 IL-4 和 IL-13 受体。这种新型药物已获得用于治疗 12 岁及以上中重度特应性皮炎患者的许可。然而，儿科人群中度普利尤单抗使用的数据仍然极其有限。本报告旨在总结度普利尤单抗在儿科人群中用于皮肤科疾病的标签内和标签外使用的现有数据。
本研究是对儿科人群中所有关于度普利尤单抗治疗皮肤科疾病的报道证据的综述。对 MEDLINE（PubMed）、clinicaltrial.gov 数据库和 SCOPUS 进行了全面检索，以查找相关文章。
文献中存在少数临床试验、病例系列和病例报告，表明度普利尤单抗在儿科患者的某些皮肤科疾病中具有令人满意的治疗效果。
需要进行更多针对更大患者群体的长期研究，以便能够对皮肤病患儿使用度普利尤单抗的疗效和安全性得出明确结论。
